Abbott patient materials describe MitraClip therapy as a minimally invasive mitral valve repair option that does not require open-heart surgery. It is used in selected patients with clinically significant mitral regurgitation after imaging and heart-team review.
Who May Be Evaluated
Abbott patient materials describe MitraClip therapy as an option for select patients with clinically significant mitral regurgitation. That includes degenerative mitral regurgitation in patients who may not be good surgical candidates and certain patients with secondary mitral regurgitation who remain symptomatic despite guideline-directed medical therapy.
In a real-world practice setting, the key question is not just whether there is leak across the mitral valve, but whether the valve anatomy, symptoms, heart function, and overall risk profile make transcatheter repair a reasonable option.
How The Procedure Works
MitraClip is a transcatheter edge-to-edge repair procedure. The device is delivered by catheter and positioned to reduce the backward leak across the mitral valve without opening the chest for conventional surgery.
That makes imaging central to planning. The team needs to understand leaflet anatomy, regurgitation severity, and whether the expected repair is likely to improve symptoms and overall hemodynamics.
Decision And Follow-Up
Follow-up after MitraClip usually centers on symptom response, echocardiographic reassessment, medication management, and whether residual mitral regurgitation remains clinically significant.
Patients with mitral regurgitation often also have heart failure, atrial fibrillation, pulmonary hypertension, or coronary disease, so the best results usually come from coordinated longitudinal care rather than from the device alone.